Alpine Immune Sciences Inc
ALPN
ALPN was delisted on the 17th of May, 2024.
180 hedge funds and large institutions have $2.56B invested in Alpine Immune Sciences Inc in 2024 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 66 increasing their positions, 42 reducing their positions, and 16 closing their positions.
294% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 16
125% more capital invested
Capital invested by funds: $1.14B → $2.56B (+$1.42B)
57% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 42
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
35% more funds holding
Funds holding: 133 → 180 (+47)
47% less call options, than puts
Call options by funds: $6.29M | Put options by funds: $11.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$170M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$58.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$43M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.1M |
| 5 |
DC
Decheng Capital
Menlo Park,
California
|
+$36.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$93.6M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$76M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$46.1M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$31.1M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$22M |
ALPN Hedge Fund Activity: Q1 2024 in Review
180 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Alpine Immune Sciences Inc (ALPN) for Q1 2024, worth a combined $2.56B — up 125% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new ALPN positions and 16 closed out — a net gain of 47 holders — while 66 added to existing stakes and 42 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $170M. The largest seller was RA Capital Management, exiting entirely with an estimated $93.6M sold.
- 180 institutional investors held Alpine Immune Sciences Inc (ALPN) as of Q1 2024, up from 133 in Q4 2023.
- Funds reported $2.56B of Alpine Immune Sciences Inc stock for Q1 2024, up 125% quarter-over-quarter.
- 63 funds opened new Alpine Immune Sciences Inc positions in Q1 2024 and 16 closed out, a net change of +47 holders.
- The largest Alpine Immune Sciences Inc buyer in Q1 2024 was Avoro Capital Advisors, an estimated $170M added.
- The largest Alpine Immune Sciences Inc seller in Q1 2024 was RA Capital Management, an estimated $93.6M sold.
Based on aggregated 13F filings for Q1 2024.